, /PRNewswire/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences:
Jefferies London Healthcare Conference, November 19-21st, 2024:
- Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, November 19th, at 2:00 pm GMT.
- TYRA management will also participate in one-on-one investor meetings and B2B meetings.
36th Annual Piper Healthcare Conference, December 3-5th, 2024, New York:
- Mr. Harris will participate in a fireside chat on Wednesday, December 4th, at 10:30 am ET.
- TYRA management will also participate in one-on-one meetings with investors.
A live and archived webcast of the fireside chats will be available via the For Investors page on the TYRA website.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology …